Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 2.73 INR
Change Today +0.03 / 1.11%
Volume 7.4K
SBIL On Other Exchanges
Symbol
Exchange
Mumbai
As of 6:00 AM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

saamya biotech india ltd (SBIL) Snapshot

Open
2.85
Previous Close
2.70
Day High
2.85
Day Low
2.70
52 Week High
09/25/14 - 6.25
52 Week Low
12/9/14 - 1.94
Market Cap
67.9M
Average Volume 10 Days
5.7K
EPS TTM
-0.27
Shares Outstanding
24.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SAAMYA BIOTECH INDIA LTD (SBIL)

Related News

No related news articles were found.

saamya biotech india ltd (SBIL) Related Businessweek News

No Related Businessweek News Found

saamya biotech india ltd (SBIL) Details

Saamya Biotech (India) Limited, a biotechnology company, focuses on the manufacture and marketing of biopharmaceuticals and recombinant protein products. The company was incorporated in 2002 and is based in Hyderabad, India.

Founded in 2002

saamya biotech india ltd (SBIL) Top Compensated Officers

Chairman and Joint Managing Director
Total Annual Compensation: 225.0K
Managing Director, Executive Director, Member...
Total Annual Compensation: 225.0K
Compensation as of Fiscal Year 2014.

saamya biotech india ltd (SBIL) Key Developments

Saamya Biotech (India) Limited Reports Unaudited Standalone Earnings Results for First Quarter Ended June 30, 2015

Saamya Biotech (India) Limited reported unaudited standalone earnings results for first quarter ended June 30, 2015. For the quarter, the company reported total income from operation of INR 67,314,705. Loss from operations before other income, finance cost and exceptional items of INR 2,391,654 compared to INR 902,287 a year ago. Loss from ordinary activities before tax was INR 2,408,200 compared to INR 959,306 a year ago. Net loss for the period was INR 2,408,200 or INR 0.10 per basic and diluted share compared to INR 959,306 or INR 0.04 per basic and diluted share for the same period a year ago.

Saamya Biotech (India) Limited, Board Meeting, Aug 12, 2015

Saamya Biotech (India) Limited, Board Meeting, Aug 12, 2015. Agenda: To consider quarterly results.

Saamya Biotech (India) Limited Announces Board Changes

Saamya Biotech (India) Limited at its board meeting held on July 6, 2015, accepted the resignation of Dr. Naveen Reddy Chitty as Director of the company with effect from July 6, 2015 and reconstitute the audit and Remuneration Committees with the appointment of Mr. Kishankumar Srishankar Jha as Non-Executive & Additional Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SBIL:IN 2.73 INR +0.03

SBIL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SBIL.
View Industry Companies
 

Industry Analysis

SBIL

Industry Average

Valuation SBIL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.2x
Price/Book 0.2x
Price/Cash Flow 18.7x
TEV/Sales 0.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAAMYA BIOTECH INDIA LTD, please visit www.saamyabiotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.